Gasperini C, Pozzilli C, Bastianello S, Koudriavtseva T, Galgani S, Millefiorini E, Paolillo A, Horsfield M A, Bozzao L, Fieschi C
Department of Neurological Sciences, University of Rome La Sapienza, Italy.
Neurology. 1998 Feb;50(2):403-6. doi: 10.1212/wnl.50.2.403.
The aim of this study was to investigate whether a concomitant treatment with recombinant interferon beta 1a (rIFN beta-1a) modifies the effect of steroids on the blood-brain barrier (BBB) in relapsing remitting MS patients, as evaluated by enhanced MRI of the brain. We evaluated 19 patients with a clinical relapse treated only with intravenous methylprednisolone (IVMP; 1 g daily for 6 days), and 10 patients who experienced a clinical relapse and were treated with IVMP (1 g daily for 6 days) during an rIFN beta-1a treatment period. The number and volume of enhancing lesions were analyzed on four serial MR images obtained at monthly intervals (one scan before and three scans after IVMP treatment). A significant reduction in the mean number and volume of enhancing lesions was seen in the first scan after IVMP treatment in all patients. However, while persistently low enhancement was seen in the follow-up scans of patients treated with rIFN beta-1a, a rebound effect (i.e., increase in the number and volume of gadolinium-enhancing lesions) was observed in the other patients during the follow-up. These data suggest that rIFN beta-1a prolongs the beneficial effect of steroids on the BBB.
本研究的目的是,通过脑部增强磁共振成像(MRI)评估,调查重组干扰素β-1a(rIFNβ-1a)联合治疗是否会改变复发缓解型多发性硬化症(MS)患者中类固醇对血脑屏障(BBB)的作用。我们评估了19例仅接受静脉注射甲基泼尼松龙(IVMP;每日1 g,共6天)治疗的临床复发患者,以及10例在rIFNβ-1a治疗期间出现临床复发并接受IVMP(每日1 g,共6天)治疗的患者。在每月间隔获取的四张连续MR图像上分析强化病灶的数量和体积(IVMP治疗前一次扫描,治疗后三次扫描)。所有患者在IVMP治疗后的首次扫描中,强化病灶的平均数量和体积均显著减少。然而,在用rIFNβ-1a治疗的患者的后续扫描中,强化持续处于低水平,而其他患者在随访期间则观察到了反弹效应(即钆增强病灶的数量和体积增加)。这些数据表明,rIFNβ-1a可延长类固醇对血脑屏障的有益作用。